TLV logotyp

Du är här:

Pharmaceutical reviews

We at any time review the reimbursement status of medicines to see if they should continue to be subsidized or not.

We review individual medicines or smaller groups of medicines, within medical areas where we judge there to be reason to question whether the medicine is cost-effective or not. The balance between medicines’ cost-effectiveness ratio changes over time, for example when new medicines are subsidized or when we accept new pricing for a medicine.

Prior to commencing a new review, we make prioritization analyses where we, among other things, consider sales volumes, reimbursement costs, cost per DDD, expanded indications and expired patents. We also hold a dialogue with the county councils and provide them with an opportunity to submit suggestions on which products we should review.

We may also start a review in connection with evaluating an application for a new medicine to be part of the reimbursement system. Such a review can take place if there are deficiencies within a specific medical area when it comes to usage or cost-effectiveness.

If a review is started the company or companies are informed by us.

Senast uppdaterad 01 augusti 2018


Måndag- fredag
09:00 - 16:00.

Växel: 09:00 -16:00.
Registratur:  09:00 -15:00.



Telefon växel: 08 - 568 420 50


Fleminggatan 18
112 26 Stockholm

Box 225 20
104 22 Stockholm

FE 909
838 74 Frösön

202 100 - 5364

Följ TLV